Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued ...

Akili, the company behind video game-like prescription and over-the-counter digital therapeutics for individuals with ADHD, has signed a definitive merger agreement with mental health and fitness ...

Akili did not respond to requests for comment from the Business Journal. Akili’s share price was about .33 cents at 12:45 p.m. on Monday, giving the company a market capitalization of $26 million.